Elliott Sigal, MD, PhD
Elliott Sigal, M.D., Ph.D. is a former executive vice president and director of Bristol-Myers Squibb. He served as chief scientific officer and president of R&D for Bristol-Myers Squibb from 2004 until 2013. Under his leadership, fourteen new medicines came to market including Erbitux (Colon Cancer), Baraclude (Hepatitis B), Orencia (Rheumatoid Arthritis), Sprycel (Leukemia), Eliquis (Stroke), and Yervoy (Melanoma). He built BMS research into a lead position in immuno-oncology which is revolutionizing the practice of medicine in cancer. In 2012, Dr. Sigal was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence.
Dr. Sigal was a principal architect of the successful Biopharma Transformation Strategy of the company and was instrumental in increasing R&D productivity, developing the company’s strategy in biologics and acquiring external innovation in Bristol’s String of Pearls initiative.
Dr. Sigal currently serves as venture partner and senior advisor to the healthcare team of New Enterprise Associates and also consults for select biotechnology companies. He is a member of the Board of Directors for Adaptimmune and Spark Therapeutics. He is co-chair of Amgen’s Scientific Advisory Board and a member of the Scientific Steering Committee for the Parker Institute for Cancer Immunotherapy. Dr. Sigal joined BMS in 1997 and held roles in both discovery and development before ascending to chief scientific officer. Positions prior to BMS included a faculty appointment at University of California, San Francisco (UCSF), senior executive roles at Syntex/Roche and CEO of the genomics firm, Mercator Genetics. Dr. Sigal received his medical degree from the University of Chicago in 1981 and trained in Internal Medicine and Pulmonary Medicine at UCSF. Prior to medical school he received a bachelor’s degree, medical degree and doctorate degree in industrial engineering from Purdue University.